Target Price | $15.10 |
Price | $7.03 |
Potential |
114.79%
register free of charge
|
Number of Estimates | 10 |
10 Analysts have issued a price target BioCryst Pharmaceuticals, Inc. 2025 .
The average BioCryst Pharmaceuticals, Inc. target price is $15.10.
This is
114.79%
register free of charge
$30.00
326.74%
register free of charge
$8.00
13.80%
register free of charge
|
|
A rating was issued by 10 analysts: 9 Analysts recommend BioCryst Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the BioCryst Pharmaceuticals, Inc. stock has an average upside potential 2025 of
114.79%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 331.41 | 444.90 |
22.37% | 34.25% | |
EBITDA Margin | -30.79% | 1.17% |
43.27% | 103.80% | |
Net Margin | -73.75% | -17.55% |
27.50% | 76.20% |
8 Analysts have issued a sales forecast BioCryst Pharmaceuticals, Inc. 2024 . The average BioCryst Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast BioCryst Pharmaceuticals, Inc. 2024 . The average BioCryst Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 BioCryst Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average BioCryst Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.18 | -0.38 |
11.28% | 67.80% | |
P/E | negative | |
EV/Sales | 4.42 |
10 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast for earnings per share. The average BioCryst Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the BioCryst Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
BioCryst Pharmaceuticals, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.